Improving oral bioavailability through inhibition of crystallization after dosing

American Pharmaceutical Review

Volumn 10, Issue 1, 2007, Pages 84-89

  Remenar, Julius F ^a  

^a Transform Pharmaceuticals

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DEXTRO ALPHA TOCOPHERYLPOLYETHYLENE GLYCOL 1000 SUCCINATE; HYDROXYPROPYLCELLULOSE; MACROGOL 400; MACROGOL DERIVATIVE; SODIUM; SOLVENT; SURFACTANT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; GASTROINTESTINAL ABSORPTION; NONHUMAN; PH; PRECIPITATION; SHORT SURVEY;

EID: 34250797439     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: an extraordinary example of conformational polymorphism. Pharmaceutical Research 2001, 18, 859-866.
2. Morissette, S. L.; Soukasene, S.; Levinson, D.; Cima, M. J.; Almarsson, Ö. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proceedings of the National Academy of Sciences of the United States of America 2003, 100, 2180-2184.
3. Bernstein, J. Polymorphism and Patents. In Polymorphism in Molecular Crystals; Oxford University Press: Oxford, 2006; pp. 303-304.
4. Johnson, K. C.; Swindell, A. C. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharmaceutical Research 1996, 13, 1795-1798.
5. Li, S.; He, H.; Parthiban, L. J.; Yin, H.; Serajuddin, A. T. M. IV-IVC considerations in the development of immediaterelease oral dosage form. Journal of Pharmaceutical Sciences 2005, 94, 1396-1417.
6. Paulson, S. K.; Vaughn, M. B.; Jessen, S. M.; Lawal, Y.; Gresk, C. J.; Yan, B.; Maziasz, T. J.; Cook, C. S.; Karim, A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. Journal of Pharmacology and Experimental Therapeutics 2001, 297, 638-645.
7. Pharmacia Corporation . 1998. Celecoxib New Drug Application. No. 20-998.
8. Tawa, M.; Remenar, J.; Peterson, M.; Almarsson, Ö.; Guzman, H.; Chen, H.; Oliveira, M. 2004. Pharmaceutical compositions with improved dissolution. Publication Number WO/2004/061433.
9. Hariharan, M.; Kararli, T.; Hassan, F.; Forbes, J. 2001. Rapidonset formulation of a selective cyclooxygenase-2 inhibitors. Publication Number WO/2001/078724.